Accordingly, the level of HER2 activation (p = 0.0107, Figure 4b,d) and the sensitivity of BC cells to trastuzumab cytotoxic activity (p = 0.1073, Figure S2a) were higher in HER2-addicted cells than in nonaddicted cells. Here, ERBB2 is linked to breast cancer.